Oral Bioavailability of GLPG0555 in Different Solid Formulations
NCT ID: NCT01278095
Last Updated: 2011-03-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
12 participants
INTERVENTIONAL
2011-01-31
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oral Bioavailability of Two Solid Formulations of GLPG0259.
NCT01322451
Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule
NCT01297595
A Study of Two Dosage Forms of LY2886721 in Healthy Participants
NCT01775904
Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential
NCT04274075
Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654
NCT06389955
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GLPG0555 solid dispersion, fasting
50 mg as solid dispersion capsule, in fasting condition
GLPG0555 solid dispersion
solid dispersion capsules, 50 mg, single dose
GLPG0555 solid dispersion, fed
50 mg as solid dispersion capsule, after breakfast
GLPG0555 solid dispersion
solid dispersion capsules, 50 mg, single dose
GLPG0555 nanosuspension, fed
50 mg as nanosuspension, given after breakfast
GLPG0555 nanosuspension
Nanosuspension, 50 mg, single dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GLPG0555 solid dispersion
solid dispersion capsules, 50 mg, single dose
GLPG0555 nanosuspension
Nanosuspension, 50 mg, single dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI between 18-30 kg/m², inclusive.
Exclusion Criteria
* smoking
* drug or alcohol abuse
18 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Galapagos NV
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Galapagos
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gerben van 't Klooster, PhD
Role: STUDY_DIRECTOR
Galapagos NV
Jos Leempoels, MD
Role: PRINCIPAL_INVESTIGATOR
SGS Stuivenberg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SGS Stuivenberg
Antwerp, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010-022457-42
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
GLPG0555-CL-103
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.